GlassScriptPhysician profile
Deandra Ransom
NPI 1679906168
$8,770.73
in general payments reported to CMS, 2019-2025
31 companies · $2,397 in 2025
The $2,397 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $967 · 2022: $1,534 · 2023: $2,107 · 2024: $1,765 · 2025: $2,397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,947 · Education: $323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,947.25 |
| Education | $322.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,259.35 | 2021-2025 | |
| Janssen Biotech, INC. | $1,062.70 | 2021-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $903.93 | 2021-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $601.88 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $584.37 | 2021-2025 | |
| Ucb, INC. | $521.69 | 2024-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $476.67 | 2021-2025 | |
| Incyte Corporation | $457.48 | 2021-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $434.35 | 2023-2024 | Sotyktu |
| Dermavant Sciences, INC. | $434.31 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $385.70 | 2021-2025 | Nemluvio, Aklief |
| Sun Pharmaceutical Industries INC. | $297.75 | 2021-2024 | Absorica Ld, Winlevi, Ilumya |
| Pfizer INC. | $227.01 | 2021-2025 | |
| Krystal Biotech INC | $166.76 | 2023-2025 | Vyjuvek |
| Amgen INC. | $154.94 | 2023-2025 | Otezla, Otezla |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $119.68 | 2023-2025 | Adbry |
| Arcutis Biotherapeutics, INC. | $108.54 | 2024-2025 | Zoryve |
| Organon LLC | $95.47 | 2025 | Vtama |
| Journey Medical Corporation | $79.80 | 2022 | |
| Janssen Scientific Affairs, LLC | $76.24 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $60.15 | 2021 | |
| Biofrontera INC. | $50.24 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Organogenesis INC. | $37.01 | 2025 | Affinity |
| Fresenius Kabi USA, LLC | $29.41 | 2024 | Idacio |
| Epi Health, LLC | $25.45 | 2022 | |
| Dermira, INC. | $23.79 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.72 | 2024 | Spevigo |
| Mayne Pharma Commercial LLC | $22.45 | 2022 | |
| Nobelpharma America, LLC | $18.87 | 2024 | |
| Next Science LLC | $16.26 | 2023 | Xperience, Blastx, Surgx |
| Genentech USA, INC. | $14.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deandra Ransom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.